Payment overview · 2025
General Payments
$589.52
14 reported records · 9 companies
Healthcare provider profile · identity verified
Mallory Quincey
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CENTRE, AL · NPI 1407374739
Verified facts
What the public records show
CMS Open Payments records show Mallory Quincey received $589.52 in general payments during 2025 across 14 reported records.
Novartis Pharmaceuticals Corporation accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $125.94 | 21.4% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $123.19 | 20.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.07 | 20.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.02 | 9.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.63 | 7.4% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $40.11 | 6.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.58 | 6.0% | 1 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $21.80 | 3.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.18 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $589.52 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $125.94 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $123.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 80 |
| Losartan Potassium | Losartan Potassium | 271 | 85 |
| Omeprazole | Omeprazole | 216 | 67 |
| Lisinopril | Lisinopril | 207 | 60 |
| Metformin Hcl | Metformin Hcl | 194 | 54 |
| Meloxicam | Meloxicam | 162 | 48 |
| Montelukast Sodium | Montelukast Sodium | 155 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 41 |
| Potassium Chloride | Potassium Chloride | 115 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 35 |
| Buspirone Hcl | Buspirone Hcl | 108 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 29 |
| Simvastatin | Simvastatin | 106 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 29 |
| Trazodone Hcl | Trazodone Hcl | 103 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 29 |
| Mounjaro | Tirzepatide | 100 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 36 |
| Furosemide | Furosemide | 89 | 34 |
| Jardiance | Empagliflozin | 89 | 18 |
| Fenofibrate | Fenofibrate | 87 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 20 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Carvedilol | Carvedilol | 82 | 25 |
| Methocarbamol | Methocarbamol | 78 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 28 |
| Ramipril | Ramipril | 73 | 16 |
| Januvia | Sitagliptin Phosphate | 71 | 16 |
| Prednisone | Prednisone | 69 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 61 | 56 |
| Glipizide | Glipizide | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 16 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 15 |
| Famotidine | Famotidine | 56 | 18 |
| Gabapentin | Gabapentin | 54 | 24 |
| Meclizine Hcl | Meclizine Hcl | 54 | 24 |
| Metformin Hcl Er | Metformin Hcl | 54 | 22 |
| Eliquis | Apixaban | 53 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 12 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 16 |
| Baclofen | Baclofen | 38 | suppressed |
| Nystatin | Nystatin | 38 | 14 |
| Doxepin Hcl | Doxepin Hcl | 37 | 19 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 29 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 23 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Atenolol | Atenolol | 28 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | 14 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Linzess | Linaclotide | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Clonidine | Clonidine | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $589.52 · 14 records | Novartis Pharmaceuticals Corporation | ELIQUIS, JARDIANCE, LEQVIO, LifeVest, NURTEC ODT, UBRELVY, VERQUVO, WATCHMAN FLX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error